You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Improved Microcalorimeter Detectors for X-ray Chemical Shift Mapping

    SBC: STAR CRYOELECTRONICS, LLC            Topic: 9020868TT

    X-ray fluorescence spectroscopy is a widely used and extremely sensitive analytical technique for qualitative and quantitative chemical analysis. Superconducting Transition Edge Sensor (TES) microcalorimeter detectors have now been developed that achieve an energy resolution of 2 eV for 1.5 keV X-rays, which is sufficient to enable the measurement of the small shift of the X-ray line position that ...

    SBIR Phase II 2013 Department of CommerceNational Institute of Standards and Technology
  2. Automated SCAP Tool Validator (ASTV)

    SBC: ATC-NY INC            Topic: 9010377R

    The current testing methods of the NIST Security Content Automation Protocol (SCAP) Validation Program are largely manual and labor-intensive, making comprehensive validation of SCAP-enabled IT security products difficult and time-consuming. ATC-NY will design and develop the Automated SCAP Tool Validator (ASTV) for use with the SCAP Public Validation Test Suite and others. ASTV automates the conf ...

    SBIR Phase I 2013 Department of CommerceNational Institute of Standards and Technology
  3. Three-Dimensional Test Materials for Solid Supports

    SBC: Prime Synthesis            Topic: 9021168R

    Since 1990, Prime Synthesis, Inc. (PSI) has been a leading manufacturer of controlled pore glass (CPG). It has developed significant expertise in the optimization of physical characteristics and chemical modifications of CPG for a variety of applications. CPG has a unique combination of attributes including a very uniform, three-dimensional, nanopore structure that is dimensionally stable in organ ...

    SBIR Phase I 2013 Department of CommerceNational Institute of Standards and Technology
  4. Novel liver fibrosis test for early detection and classification

    SBC: IMMUNOTOPE, INC.            Topic: NIAAA

    DESCRIPTION (provided by applicant): The overall goal of this application is to develop and validate a potential biomarker based assay to determine if it can be used as a noninvasive test to detect the stage of hepatic fibrosis and to predict fibrosis progression in HIV/HCV co-infected patients. Significant fibrosis and cirrhosis are premalignant conditions that greatly increase the risk of the de ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. A Diarylheptanoid Scaffold to Treat Taopathies

    SBC: ALS BIOPHARMA, LLC            Topic: NIA

    DESCRIPTION: We identified the Myrica cerifera (Southern Bayberry) extract using a systematic screen as a potent reducer of the structural protein tau, which accumulates in a group of diseases called the tauopathies . The most prevalent tauopathy is Alzheimer's disease, for which there is renewed interest in the identification of tau- based therapeutic approaches to treat this devastating d ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. DC-SIGN Inhibitors for the Treatment of HIV Infection

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): DC-SIGN (dendritic cell specific ICAM-3-grabbing non-integrin), a membrane protein of C-type lectin family, is found in high levels on monocyte-derived DCs, some macrophages, and activated B cells. In vivo, DC-SIGN- positive cells were demonstrated in lymph nodes, tonsils, skin, and the subepithelial region of the cervix. DC- SIGN has been shown to bind to a nu ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Biomarker discovery for immunodiagnosis of invasive candidiasis

    SBC: DXDISCOVERY INC            Topic: NIAID

    DESCRIPTION (provided by applicant): Invasive candidiasis (IC) is one of the most serious threats to patients in a critical setting. With as many as 60,000 cases per year in the U.S., the total cost associated with IC in the U.S. may be as high as 2-4 billion/year. One of the most critical factors influencing patient outcome is early diagnosis. The goal of this project is a rapi and inexpensive i ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. New therapeutics for the treatment of Acinetobactor baumannii infections.

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Acinetobacter are strictly aerobic, non-fermentative Gram-negative bacilli that are of major concern in human health, in particular the species Acinetobacter baumannii. They are responsible for clinically important infections that cause a wide variety of maladies including pneumonia, skin and wound infections, bacteremia and meningitis. In addition, A. baumanni ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Polaris Oncology Survivor Transition (POST) System

    SBC: POLARIS HEALTH DIRECTIONS, INC            Topic: NCI

    DESCRIPTION (provided by applicant): The Institute of Medicine (IOM) strongly recommends that all breast cancer patients who are ending active treatment have a survivorship plan. Such a plan should assist patients in moving back to their primary care physician (PCP), provide advice for reducing risk for cancer recurrence or new cancer development, and address the remaining psychosocial challenge ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Clinical Translation of an Anti-Metastatic Antibody for Breast Cancer Therapy

    SBC: FOR-ROBIN, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): This proposal aims to develop a novel, highly-specific targeted therapy for treatment of breast cancer. The long-term objective is to convert the proprietary intellectual property, the mouse monoclonal antibody (McAb)JAA-F11, which targets the pancarcinoma Thomsen-Friedenreich antigen (TF-Ag) to a humanized form for use as an adjunct with conventional therapy ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government